Abstract
Objective: We described the magnitude, type, and factors associated with first-line antiretroviral therapy (ART) modification in HIV-1-infected adults on ART in Jos, Nigeria. Method: Data on 6309 patients initiated on first-line ART between January 2004 and December 2006 were analyzed retrospectively. Factors predictive of modification to initial ART were assessed by chi-square and multivariable logistic regression analysis. Results: Overall, 5212 (83%) included patients incurred a modification (73.3% drug substitution and 9.7% drug switch) to their initial first-line ARV regimen during a median (interquartile range) follow-up period of 7 (3-8) years. Drug substitutions of zidovudine (ZDV) were less likely than of tenofovir (TDF; adjusted odd ratio [AOR] 0.6; 95% confidence interval [CI]: 0.51-0.71), and Drug substitutions of efavirenz (EFV) were more likely than of nevirapine (NVP)- containing (AOR 1.82; 95% CI: 1.42-2.33) regimens. Predictors of switch to second-line regimen include older age (AOR 2.05; 95% CI: 1.68-2.51), CD4 count ≥100 cells/mm3 (AOR 1.89; 95% CI: 1.49-2.37), EFV compared to NVP (AOR 1.38; 95% CI: 1.02-1.88), and drug toxicity (AOR 1.90; 95% CI: 1.48-2.43). Conclusion: Modification to initial ART was common in this study. Further evaluation of the contribution of guideline changes on regimen modification and treatment outcomes is recommended.
Original language | English (US) |
---|---|
Pages (from-to) | 348-354 |
Number of pages | 7 |
Journal | Journal of the International Association of Providers of AIDS Care |
Volume | 14 |
Issue number | 4 |
DOIs | |
State | Published - Jul 25 2015 |
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded in part by the US Department of Health and Human Services, Health Resources and Services Administration (U51HA02522), and the Centers for Disease Control and Prevention (CDC) through a cooperative agreement with APIN (PS 001058). We are grateful to the Fogarty International Center, Northwestern University AIDS International Training and Research Program (Grant Numbers R24TW008878 & D43TW007995) for training support and mentorship toward this manuscript. The contents are solely the responsibility of the authors and do not represent the official views of the funding institutions.
Keywords
- antiretroviral therapy
- regimen durability
- substitution
- switch
ASJC Scopus subject areas
- Infectious Diseases
- Dermatology
- Immunology